Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesLaboratory/Pathologymedical mutual - ohio immunohistochemistry Coverag…
    Ask Trek AI about this page
    Currentmedical mutual - ohioPolicy AHS - P2018 - Immunohistochemistry

    Immunohistochemistry

    Customize your policy alerts

    Sign up for medical mutual - ohio Policy AHS - P2018 - Immunohistochemistry alerts

    Get alerted when Policy AHS - P2018 - Immunohistochemistry changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines coding, coverage limitations, terminology, scientific background, and analytic validation expectations for immunohistochemistry and multiplex IHC used in diagnostic pathology; applies to providers submitting IHC testing for Medical Mutual - Ohio members.

    Policy Summary
    Payermedical mutual - ohio
    PolicyImmunohistochemistry
    Policy CodePolicy AHS - P2018 - Immunohistochemistry
    Change TypeReview — no material clinical or coverage changes
    Effective DateJun 1, 2026
    Last ReviewDec 3, 2025
    Next Review Date
    Key ActionLaboratories must maintain analytic validation and verification documentation for IHC assays, including concordance testing and validation case counts.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    88341-88344Procedure codes referenced
    90% concordanceCAP validation benchmark
    20/20Validation minima (LDT)
    10/10Cytology validation minima
    12/03/2025Last review

    Coverage Criteria and Validation Requirements

    Analytic Validation and Guideline-based Testing

    Laboratory analytic validation, quality control, and guideline-based testing recommendations (apply as noted):

    Validation case-counts for LDTs: For laboratory-developed assays with both predictive and nonpredictive applications using the same scoring criteria, test a minimum of 20 positive and 20 negative cases.20 positive and 20 negative

    CAP recommendation for predictive markers

    Cytologic specimen validation: Perform separate validations for every new analyte and fixation method for cytologic specimens not fixed the same as tissues used in initial validation; a minimum of 10 positive and 10 negative cases is recommended, or document rationale if fewer.10 positive and 10 negative

    CAP guidance; document rationale if fewer than recommended

    Revalidation triggers: Confirm assay performance with increased controls or revalidation when changing antibody dilution, antibody vendor (same clone), incubation or retrieval times, fixative type, antigen retrieval method, detection system, tissue processing equipment, automated testing platform, environmental conditions, or when placing a new antibody lot into service.see node text

    CAP lists specific changes that trigger confirmation or revalidation

    Full revalidation required: Run a full revalidation equivalent to initial analytic validation when the antibody clone is changed for an existing validated assay.full revalidation

    CAP requirement when antibody clone is changed

    Analytic validation documentation: Maintain analytic validation and verification documentation for LDTs and FDA-cleared IHC assays, including concordance testing and counts of positive and negative validation tissues as described by CAP guidance; document justification when fewer than recommended validation cases are used.documented validation records

    Laboratory medical director responsibility per CAP; maintain records for audits

    Guideline-based tumor biomarker testing (HER2/HR): Follow ASCO/CAP recommendations for HER2 and hormone receptor testing in breast cancer: perform HER2 testing on all newly diagnosed breast cancers and on metastatic sites when available; use concomitant IHC review with ISH per ASCO/CAP and prefer dual-probe ISH where recommended. Follow CAP/ASCO quality control and reporting protocols.per ASCO/CAP guidance

    ASCO/CAP recommendations affirmed through 2023

    NCCN and ESMO testing recommendations: Adhere to NCCN recommendations for IHC/MSI testing (eg, universal screening in colorectal cancer using IHC and/or MSI) and use IHC per NCCN-endorsed CAP/ASCO protocols; for cancers of unknown primary, follow ESMO guidance that histology and IHC on good-quality tissue are required.per NCCN/ESMO

    NCCN endorses CAP/ASCO protocols; ESMO supports IHC for cancers of unknown primary

    The policy notes that there is no specific, generally accepted guidance on the selection or number of antibodies to use for most immunohistochemistry evaluations. As written, the document does not establish explicit coverage exclusions based on antibody selection or panel size; instead, it references that IHC use and antibody choices are informed by multiple specialty society recommendations and by individual clinical context.

    If a conflict exists between this policy and an applicable government policy (for example, Medicare Local Coverage Determinations or National Coverage Determinations, or state Medicaid policies), the government policy governs determinations. Providers should consult the CMS coverage database and relevant state Medicaid resources for the most current authoritative guidance.

    The policy was reviewed on 12/03/2025. The literature review performed at that time did not require any modifications to the existing coverage criteria.

    Indications and Accepted Uses

    Diagnostic evaluation of tumors, tissue/cell origin, benign vs malignant differentiation, infectious organism identification, and targeted therapy selection

    Diagnostic evaluation of tumors, tissue/cell origin, benign vs malignant differentiation, infectious organism identification, and selection of targeted therapies — common marker panels include:

    Lung adenocarcinoma: TTF1; napsin A.
    Breast carcinoma: GATA3; ER; GCDFP15.
    Urothelial carcinoma: GATA3; UPII; S100P; CK903; p63.
    Squamous cell carcinoma: p40; CK5/6.

    Procedure Coding and Validation Metrics

    Applicable CPT Procedure Codes and usage rulesCPT
    88342First single antibody procedure; reimbursed at one unit per specimen, up to four specimens per date of service
    88341Each additional single antibody per specimen; reimbursed up to a maximum of 13 units per date of service
    88344Each multiplex antibody per specimen; reimbursed up to six specimens per date of service
    Applicable CPT CodesCPT
    88341Immunohistochemistry or immunocytochemistry, per specimen; each additional single antibody stain procedure.
    88342Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain.
    88344Immunohistochemistry or immunocytochemistry, per specimen; each multiplex antibody stain procedure.
    inv-07: Analytic validation concordance — performance benchmark
    Analytic concordance benchmark>= 90% overall concordance between the new assay and the comparator assay for initial analytic validation or verification
    Source guidanceCollege of American Pathologists (CAP) requirement for initial analytic validation/verification
    ApplicabilityApplies to all laboratory-developed IHC assays and verification of FDA-cleared IHC assays before reporting patient results

    Billing, Documentation, and Laboratory Responsibilities

    Billing Rule

    CPT coding and unit limits

    Use CPT codes 88342, 88341, and 88344 with the stated per-specimen and per-date-of-service unit limits; ensure units billed match the number of specimens and antibody type (single vs multiplex). Code 88342 is for the first single antibody per specimen (one unit per specimen, up to four specimens per date of service); 88341 is for each additional single antibody per specimen (reimbursed up to 13 units per date of service); 88344 is for each multiplex antibody per specimen (up to six specimens per date of service).

    • Bill 88342 once per specimen for the initial single-antibody stain (max 4 specimens/ date of service).
    • Bill 88341 for each additional single-antibody stain per specimen (aggregate limit 13 units/date of service).
    • Bill 88344 per specimen for each multiplex antibody stain (max 6 specimens/date of service).
    Billing Rule

    Procedure coding guidance for 88342 / 88341 / 88344

    Who Should Order and Ordering Constraints

    Note

    No specific ordering restrictions in this policy

    No specific ordering restrictions are stated in this policy; ordering and coverage depend on the member’s benefits and applicable state/federal regulations.

    Step Therapy

    Expected ordering by treating pathology/laboratory personnel per guidance

    Testing is expected to be ordered by treating pathology or laboratory personnel in accordance with professional guidance (eg, NCCN, ASCO/CAP); follow those guideline-based ordering practices.

    • Order IHC and/or MSI for universal CRC screening per NCCN recommendations
    • Follow ASCO/CAP protocols for HER2, HR testing and other guideline‑recommended assays

    Limitations and Non-covered Items

    Laboratory-developed tests (LDTs) used for IHC are not currently required to have FDA clearance or approval for clinical use; however, they are regulated under CLIA as high-complexity tests and must be validated and performed in-house in accordance with applicable regulatory and accreditation standards.

    Scientific Background and Technology Overview

    Immunohistochemistry (IHC) is a staining technique that uses labeled antibodies to detect specific antigens in cells or tissue sections. IHC is applied across diagnostic pathology to differentiate benign from malignant lesions, determine tumor origin or subtype, identify infectious organisms, and inform targeted therapy selection based on marker expression. Multiplex IHC (mIHC) extends these capabilities by allowing detection of multiple targets simultaneously in a single tissue section, which can assist in characterizing the tumor microenvironment and in immunotherapy stratification.

    Key Terms and Definitions

    inv-17: Immunohistochemistry (IHC) — definition of IHC technique
    DefinitionImmunohistochemistry (IHC) is a staining technique that uses specific antibodies and a biochemical label to detect target antigens and identify cells, tissues, or organisms
    Primary usesDifferentiate tumor types, determine tissue/cell origin, distinguish benign vs malignant lesions, identify infectious organisms, and guide therapy selection
    Key featuresVisualization of antigen–antibody interaction by a biochemical tag; interpretation typically relies on a panel of markers rather than a single stain
    inv-18: Multiplex IHC (mIHC) — definition and capability summary
    DefinitionMultiplex immunohistochemistry (mIHC) is an IHC technique that allows detection of multiple targets simultaneously in a single tissue section
    Capabilities

    Policy Review and Revision Timeline

    2025-12-03reviewLatest

    Literature review and policy update: background, guidelines/recommendations, and evidence-base updated; literature review did not require changes to coverage criteria.

    Policy Summary
    Payermedical mutual - ohio
    PolicyImmunohistochemistry
    Policy CodePolicy AHS - P2018 - Immunohistochemistry
    Change TypeReview — no material clinical or coverage changes
    Effective DateJun 1, 2026
    Last ReviewDec 3, 2025
    Next Review Date
    Key ActionLaboratories must maintain analytic validation and verification documentation for IHC assays, including concordance testing and validation case counts.
    SourceLink
    On This Page
    Coverage Criteria and Validation RequirementsIndications and Accepted UsesProcedure Coding and Validation MetricsBilling, Documentation, and Laboratory ResponsibilitiesWho Should Order and Ordering ConstraintsLimitations and Non-covered ItemsScientific Background and Technology OverviewKey Terms and DefinitionsPolicy Review and Revision Timeline
    Renal cell carcinoma (clear cell): PAX8; RCCma; pVHL; KIM-1.
    Papillary RCC: P504S; RCCma; pVHL; PAX8; KIM-1.
    Translocational RCC: TFE3.
    Hepatocellular carcinoma: Arginase-1; glypican-3; HepPar-1.
    Adrenal cortical neoplasm: Mart-1; inhibin-a; calretinin; SF-1.
    Melanoma: S100; Mart-1; HMB-45; MiTF; SOX10.
    Merkel cell carcinoma: CK20 (perinuclear dot staining); MCPyV.
    Mesothelial origin: Calretinin; WT1; D2-40; CK5/6; mesothelin.
    Neuroendocrine origin: Chromogranin; synaptophysin; CD56.
    Upper GI tract tumors: CDH17; CDX2; CK20.
    Lower GI tract tumors: CDH17; SATB2; CDX2; CK20.
    Pancreatic neoplasms: (acinar) Glypican-3; antitrypsin. (ductal) MUC5AC; CK17; Maspin; S100P; IMP3. (neuroendocrine) PR; PAX8; PDX1; CDH17; islet-1.
    Prostate adenocarcinoma: PSA; NKX3.1; PSAP; ERG.
    Ovarian serous carcinoma: PAX8; ER; WT1.
    Ovarian clear cell carcinoma: pVHL; HNF-1b; KIM-1; PAX8.
    Germ cell and related tumors: Seminoma: SALL4, OCT4, CD117, D2-40. Yolk sac tumor: SALL4, glypican-3, AFP. Embryonal carcinoma: SALL4, OCT4, NANOG, CD30. Choriocarcinoma: b-HCG, CD10, SALL4.
    Sarcomas and spindle/round cell tumors: Synovial sarcoma: TLE1, cytokeratin. Alveolar soft part sarcoma: TFE3. Rhabdomyosarcoma: Myogenin, desmin, MyoD1. Ewing sarcoma/PNET: NKX2.2, CD99, Fli-1. Low-grade fibromyxoid sarcoma: NY-ESO-1. Epithelioid sarcoma: loss of INI1, CD34, CK.
    Hematologic and other entities: Follicular dendritic cell tumor: CD21, CD35. Mast cell tumor: CD117, tryptase. Myeloid sarcoma: CD43, CD34, MPO.
    IHC utility summary: IHC panels are used to differentiate benign from malignant lesions, determine tissue/cell origin of metastases, identify infectious organisms, and inform selection of targeted therapies (eg, HER2, ER, PR, pan-Trk, PD-L1).

    Diagnostic, prognostic, and predictive biomarker testing in cancers (guideline-supported)

    Diagnostic, prognostic, and predictive biomarker testing in cancers (guideline-backed examples):

    Breast cancer — HER2 and hormone receptors: Perform HER2 testing for all newly diagnosed breast cancer patients and on metastatic sites when available; assess HER2 using ASCO/CAP criteria with concomitant IHC review of ISH results as recommended; perform ER and PR testing by IHC on any new primary or newly metastatic breast cancer per ASCO/CAP and NCCN-endorsed protocols.per ASCO/CAP and NCCN
    Colorectal cancer — MMR/MSI screening: Use IHC for MMR protein expression and/or MSI testing for universal screening of colorectal cancer to identify mismatch repair deficiency as recommended by NCCN; tumor testing with IHC and/or MSI is the primary approach for pathology-lab-based universal screening.per NCCN
    Cancers of unknown primary: For cancers of unknown primary, perform histology and IHC on good-quality tissue specimens to help identify origin, per ESMO guidance.per ESMO
    Guideline conformity: Follow ASCO/CAP, NCCN, and ESMO recommendations for test selection, quality control, interpretation, and reporting of diagnostic, prognostic, and predictive IHC biomarkers.

    When billing IHC procedures, designate 88342 for the initial single-antibody stain per specimen and 88341 for each additional single-antibody stain; use 88344 for multiplex antibody stains—apply these code definitions per specimen as described in the CPT listings.

    • 88342 = initial single antibody stain (per specimen).
    • 88341 = each additional single antibody stain (per specimen).
    • 88344 = each multiplex antibody stain (per specimen).
    Prior Authorization

    Match coding to specimen counts

    Ensure coding and documentation reflect the exact specimen count and antibody type; misalignment between specimen counts and units billed risks denial or reimbursement adjustment.

    • Verify number of specimens on the pathology report matches units billed for 88342/88341/88344.
    Note

    Defer to applicable government policies

    Confirm that determinations for coverage or reimbursement will follow applicable government policies (LCDs/NCDs/Medicaid); when a conflict exists, the government policy governs the determination.

    • Defer to LCDs, NCDs, and state Medicaid policy where applicable.
    Documentation Required

    Maintain analytic validation and verification records

    Maintain complete analytic validation and verification documentation for all laboratory-developed tests (LDTs) and for verification of FDA-cleared IHC assays, including concordance testing and counts of positive and negative validation tissues as described by CAP guidance.

    • Retain documentation showing >=90% overall concordance for initial validation/verification where applicable.
    • Document counts of positive and negative tissues used in validation per CAP recommendations.
    Documentation Required

    Document validation case counts and rationale for fewer cases

    Document the number of validation cases and the laboratory medical director's rationale whenever fewer than the CAP-recommended minimum cases are used (for example, when fewer than 10 positive/10 negative cases are used for cytologic validations or fewer than 20/20 for predictive assays).

    • If fewer than 10 positive and 10 negative cytologic cases are used, record the rationale in the validation file.
    • If the laboratory medical director accepts fewer than 20/20 (or 40 when specified) for predictive markers, document the justification.
    Denial Risk

    Coding-based denial risk for incorrect CPT use

    Incorrect CPT coding or failure to adhere to the specimen-unit limits (for example, not using 88342 as the first single-antibody per specimen or exceeding unit maximums for 88341/88344) may lead to reimbursement denials or adjustments.

    • 88342 must be used as the first single-antibody procedure per specimen; billing otherwise risks denial.
    • Exceeding the stated per-date-of-service unit caps for 88341 or specimen limits for 88342/88344 can cause reimbursement issues.
    Note

    Government policy controls in conflicts

    When this policy conflicts with any relevant government policy (LCD/NCD/Medicaid), determinations will be made in accordance with the government policy rather than this policy.

    • Review applicable LCDs, NCDs, and state Medicaid rules for members before final determination.
    Characterizes the tumor microenvironment (vascular architecture, hypoxia, proliferation, cell death) and provides quantitative data on tumor‑infiltrating immune cells
    Clinical utilityMay improve immunotherapy stratification and enable development of parameter tumor maps
    inv-19: Predictive marker — definition entry
    DefinitionPredictive marker: a biomarker used to predict response to a specific therapy and to guide treatment decisions
    Examples in policy contextHER2, ER, PR, PD-L1 and other markers used to direct targeted or systemic cancer therapies
    Validation implicationPredictive markers require more rigorous analytic validation (eg, separate validation of scoring systems with minimum recommended case counts per CAP guidance)
    inv-20: LDT — laboratory-developed test definition and CLIA context
    DefinitionLaboratory‑developed test (LDT): an assay developed and validated by the performing laboratory and regulated under CLIA as high‑complexity testing
    Validation requirementLDTs must undergo analytic validation per CAP; for predictive LDTs, a minimum of 20 positive and 20 negative tissues is recommended
    DocumentationLaboratories must retain validation and verification documentation and document rationale when fewer than recommended cases are used